ArticlemBio2025
Interferon-stimulated circHOMER1 attenuates antiviral innate immunity.
Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circular RNAScience advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
In an initial screening of virus-induced differentially expressed circRNAs, circHOMER1 was significantly upregulated. However, its role in antiviral innate immunity remained unclear. circHOMER1 was upregulated in response to a range of stimuli, including RNA viruses, DNA viruses, as well as type I IFNs. Overexpression of circHOMER1 reduced the virus-induced type I IFN signaling pathway and promoted viral replication. Consistently, knockdown of circHOMER1 yielded opposite consequence. Mechanistically, circHOMER1 acted as a competitive endogenous RNA (ceRNA) for miR-145-3p, controlling the mRNA level of OTU domain-containing protein 7B (OTUD7B), thereby downregulating interferon regulatory factor 3 (IRF3) expression. Furthermore, circHOMER1 was found to disrupt the interaction between Ras GTPase-activating protein-binding protein 1 (G3BP1) and retinoic-acid-inducible protein I (RIG-I), impairing the detection of viral RNAs by RIG-I. Notably, the concordant immunosuppressive effects of circHOMER1 were observed in mouse infection models. These findings identify circHOMER1 as a novel interferon-stimulated circRNA that serves as a negative modulator of the antiviral innate immune response and is essential for immune homeostasis. IMPORTANCE: A growing body of evidence suggests that circRNAs are involved in various physiological or pathological processes. Through circRNA microarray screening of virus-induced differentially expressed circRNAs, we identified an upregulated circRNA, circHOMER1. circHOMER1 is abundantly expressed in the brain. The known functions of circHOMER1 have been focused on the nervous systems and the related diseases. Its functions in the immune system are not discovered. In this study, we found that circHOMER1 is upregulated by viral infection, interferon treatment, etc. circHOMER1 can negatively modulate virus-induced type I IFN signaling by acting as a ceRNA or other mechanism. The regulatory function of circHOMER1 in innate immunity is critical for immune homeostasis. The dysregulation of circHOMER1 may be associated with virus encephalitis or other related diseases. circHOMER1 may be a potential therapeutic target of virus-induced infections and autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.